HealthVerity Blog

How RWE can support drug development during COVID-19 and beyond: Q&A with Dr. Diana Brainard of Gile...

The COVID-19 pandemic introduced novel challenges for global biopharma organizations, as many adapted their clinical trial operations while working to develop lifesaving interventions. At Gilead Sciences, this need to quickly pivot led to an increase...

Data ecosystem

HealthVerity Patient Confidence Index (HVPCI) sees its highest score as patients continue to seek ca...

July 9, 2020 - Philadelphia, PA - HealthVerity announced the biweekly update to its HealthVerity Patient Confidence Inde...

Driving the new generation of value-based agreements

Value-based agreements unite pharma companies and payers with a mutually beneficial payment model, all while keeping the...

HealthVerity pulse: Q2 in review

Throughout the past quarter, we’ve announced major collaborations, built on existing partnerships and continued to suppo...

Thought leadership

HealthVerity Patient Confidence Index (HVPCI) upgraded to Critical as physician visits rise sharply

June 25, 2020 - Philadelphia, PA - HealthVerity announced the biweekly update to its HealthVerity Patient Confidence Ind...

Webinar recap: RWE and real-time insights in the COVID-19 era

During yesterday’s webinar, RWE and real-time insights: How to advance regulatory and commercial strategy in the COVID-1...

Thought leadership

HealthVerity Patient Confidence Index (HVPCI) downgraded to Severe as telehealth visits diminish

June 11, 2020 - Philadelphia, PA - HealthVerity announced the biweekly update to its HealthVerity Patient Confidence Ind...

Thought leadership

HealthVerity Patient Confidence Index (HVPCI) advances to Critical even as telehealth visits plateau

May 28, 2020 - Philadelphia, PA - HealthVerity announced the biweekly update to its HealthVerity Patient Confidence Inde...